Ligand id: 8093

Name: tildrakizumab

Compound class Antibody
Approved drug? Yes (EMA & FDA (2018))
International Nonproprietary Names
INN number INN
9672 tildrakizumab
Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
Database Links
Specialist databases
IMGT/mAb-DB 450
Other databases
GtoPdb PubChem SID 249565773
Search PubMed clinical trials tildrakizumab
Search PubMed titles tildrakizumab
Search PubMed titles/abstracts tildrakizumab
Wikipedia Tildrakizumab